Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine

Vaccine

Volumn 28, Issue 32, 2010, Pages 5179-5184

  Ronan, Edward O ^a   Lee, Lian Ni ^a   Tchilian, Elma Z ^a   Beverley, Peter C L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Ad85A; NALT; Tuberculosis

Indexed keywords

ADENOVIRUS VECTOR; BCG VACCINE; GAMMA INTERFERON; RECOMBINANT VACCINE; ACYLTRANSFERASE; ANTIGEN 85A, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; LYMPHOCYTE COUNT; MOUSE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT; ADENOVIRIDAE; ANIMAL; COMPARATIVE STUDY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; LYMPHOID TISSUE; NOSE; TUBERCULOSIS;

ACYLTRANSFERASES; ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BCG VACCINE; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; LUNG; LYMPHOID TISSUE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; NOSE; TUBERCULOSIS; VACCINES, SYNTHETIC;

EID: 77954959611     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.075     Document Type: Article

References (36)

1. Global tuberculosis control Epidemiology, strategy and financing. WHO report 2009 2009, World Health Organisation.
2. Barker L.F., Brennan M.J., Rosenstein P.K., Sadoff J.C. Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 2009, 21(3):331-338.
3. Santosuosso M., McCormick S., Zhang X., Zganiacz A., Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006, 74(8):4634-4643.
4. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173(10):6357-6365.
5. Xing Z., McFarland C.T., Sallenave J.M., Izzo A., Wang J., McMurray D.N. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One 2009, 4(6):e5856.
6. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V., Beverley P.C., et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181(7):4955-4964.
7. Santosuosso M., McCormick S., Roediger E., Zhang X., Zganiacz A., Lichty B.D., et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol 2007, 178(4):2387-2395.
8. Santosuosso M., Zhang X., McCormick S., Wang J., Hitt M., Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 2005, 174(12):7986-7994.
9. Ronan E.O., Lee L.N., Beverley P.C., Tchilian E.Z. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS One 2009, 4(12):e8235.
10. Jeyanathan M., Mu J., McCormick S., Damjanovic D., Small C.L., Shaler C.R., et al. Murine airway luminal anti-tuberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. Am J Respir Crit Care Med 2009.
11. Zuercher A.W., Coffin S.E., Thurnheer M.C., Fundova P., Cebra J.J. Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J Immunol 2002, 168(February (4)):1796-1803.
12. Kiyono H., Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4(9):699-710.
13. Bienenstock J., McDermott M.R. Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 2005, 206:22-31.
14. Sabirov A., Metzger D.W. Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue. Vaccine 2008, 26(12):1566-1576.
15. Wiley J.A., Tighe M.P., Harmsen A.G. Upper respiratory tract resistance to influenza infection is not prevented by the absence of either nasal-associated lymphoid tissue or cervical lymph nodes. J Immunol 2005, 175(5):3186-3196.
16. Liang S., Mozdzanowska K., Palladino G., Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 1994, 152(4):1653-1661.
17. Phillpotts R.J., Brooks T.J., Cox C.S. A simple device for the exposure of animals to infectious microorganisms by the airborne route. Epidemiol Infect 1997, 118(1):71-75.
18. Minne A., Louahed J., Mehauden S., Baras B., Renauld J.C., Vanbever R. The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 2007, 122(3):316-325.
19. Menzel M., Muellinger B., Weber N., Haeussinger K., Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine 2005, 23(43):5113-5119.
20. Scott G.H., Sydiskis R.J. Responses of mice immunised with Influenza virus by aerosol and parenteral routes. Infect Immun 1976, 13(3):696-703.
21. Wiley J.A., Hogan R.J., Woodland D.L., Harmsen A.G. Antigen-specific CD8 (+) T cells persist in the upper respiratory tract following influenza virus infection. J Immunol 2001, 167(6):3293-3299.
22. Tatsis N., Fitzgerald J.C., Reyes-Sandoval A., Harris-McCoy K.C., Hensley S.E., Zhou D., et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007, 110(6):1916-1923.
23. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182(12):8047-8055.
24. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(7):843-850.
25. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8(4):369-377.
26. Vordermeier H.M., Villarreal-Ramos B., Cockle P.J., McAulay M., Rhodes S.G., Thacker T., et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009, 77(8):3364-3373.
27. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(12):4781-4789.
28. Kannanganat S., Kapogiannis B.G., Ibegbu C., Chennareddi L., Goepfert P., Robinson H.L., et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 2007, 81(21):12071-12076.
29. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
30. Khader S.A., Cooper A.M. IL-23 and IL-17 in tuberculosis. Cytokine 2008, 41(2):79-83.
31. Beverley P.C., Tchilian E.Z. Lessons for tuberculosis vaccines from respiratory virus infection. Expert Rev Vaccines 2008, 7(8):1165-1172.
32. Russell M.W., Ogra P.L. Mucosal decisions: tolerance and responsiveness at mucosal surfaces. Immunol Invest 2010, 39(4-5):297-302.
33. Garcia-Contreras L., Wong Y.L., Muttil P., Padilla D., Sadoff J., Derousse J., et al. Immunization by a bacterial aerosol. Proc Natl Acad Sci USA 2008, 105(12):4656-4660.
34. Etchart N., Baaten B., Andersen S.R., Hyland L., Wong S.Y., Hou S. Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. Eur J Immunol 2006, 36(5):1136-1144.
35. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4(9):e6999.
36. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(4):422-434.